
A long‑standing mystery in the deadliest breast cancer just yielded 81 new treatment targets
Researchers have solved a long-standing mystery of how abnormal chromosomes drive cancer, identifying 81 new genes involved in aggressive breast cancer.

Researchers have solved a long-standing mystery of how abnormal chromosomes drive cancer, identifying 81 new genes involved in aggressive breast cancer.

Biohub researchers have performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, then used an AI model to mine the results for overlooked drug targets for psoriasis.

Stem cell transplantation (also called bone marrow transplantation) and gene therapy are among the most powerful curative approaches for blood diseases such as sickle cell disease, b-thalassemia, immune deficiencies and some blood cancers.

Vera Therapeutics’ atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA approval.

A collaborative research team led by National Yang Ming Chiao Tung University and National Taiwan University investigated the therapeutic potential of gene therapy administered after birth.

Sensitive test looking for key genetic mutation detects high-risk patients missed by standard testing

New research shows that the only vaccine being tested to prevent and treat schistosomiasis can do both, and the researcher who made it possible is Afzal Siddiqui, Ph.D., from the Texas Tech University Health Sciences Center (TTUHSC).

Now, new AI-aided vaccine technology developed by scientists at Cambridge University offers potential immunity against whole families of viruses and could even prevent the next pandemic, according to researchers.

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers scientists’ expertise to find viable target antigens for CAR T cell therapy.

A new study from RCSI University of Medicine and Health Sciences demonstrates a novel approach in anticancer vaccine development. The results, published in Molecular Therapy Oncology, present the first preclinical evidence showing the efficacy of an mRNA vaccine in targeting neuroblastoma, the deadliest childhood cancer.